Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...

Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment ...

Explore how pembrolizumab blocks PD-1, why responses vary across cancers, and how PD-L1, MSI/dMMR, TMB, resistance, and ...

The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. The National Comprehensive Cancer Network (NCCN) has ...

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on ...

Merck’s Keytruda plus Padcev receives European Commission approval to treat adults with resectable muscle-invasive bladder cancer: Rahway, New Jersey Friday, October 23, 2026, 1 ...

FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.

Merck & Moderna to present positive results from phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda at ESMO 2026 Presidential Symposium: Rahway, New Jersey Saturday ...

Sun Pharmaceutical's Unloxcyt is recommended in cancer care guidelines as a significant treatment option for locally advanced ...

The updated recommendation adds to the drug’s existing Category 2A designation for metastatic cutaneous squamous cell ...

The recommendation adds to UNLOXCYT’s Category 2A designation for metastatic cutaneous squamous cell carcinoma, assigned in ...

SALT LAKE CITY -- — Jaren Jackson Jr. had 24 points and 10 rebounds, rookie Darryn Peterson made the go-ahead free throws with 50.5 second left, and the Utah Jazz outlasted the New Orleans Pelicans ...